We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The boss has signalled a retreat for now. Tomorrow Let’s combat any further shallow and disruptive thinking thinking with lots of evidence based views.
ndr50. Salfordred.
I'm off to struggle with the research - its like homework...going through endless pharma papers about inhibitors and oncogenes, I'd so much rather go and see the new Wes Anderson film again - or just spout cr*p about covid and the sp. Thats also easy. Thanks for the guidance people. take care all.
ndr50 , totally agree with your thoughts, cancer research in my mind was always the prime objective, Covid came in by the side door so to speak , as you rightly say Sareum may well benefit by future knowledge and research.
Steadydanny absolutely agree it’s a small part of Sar are about. However it may have provided additional value in the nearer term. This was not overlooked by many on this bb during the last year. Sareum’s ipr will hopefully yield transformational returns in the future that’s why I’m invested. I’m just pointing out that delays have consequences. Things will be moving next year in the Tyk2 pharma area as well although we still have the only Tyk2 available to license. I’m looking forward to the toxicology results and the phase 1 data. Deals t/o’s who knows exactly what the BOD have been discussing with third parties? It’s mostly all conjecture until an RNS lands.
Ndr you are focusing on covid. We had a grant to look into covid. But 90 percent of our ipr is elsewhere. Why are you making covid sareums mainstay ipr reason of being?
Steadydanny I’m aware of the statements in these RNSs. What we now know from the latest RNS is that no real progress has been made as regards an application to Covid since the positive human lung cell results were reported on July 1st other than perhaps the consultation of experts. If we get an RNS stating that we are applying for Agile funding or another route to take this forward then that would be great. Otherwise we can only rely on information requested under FOI requests. So far the statements have been vague with no definite plan of action being outlined. Unless there is some way of a fast track for Covid we are looking at end of 2022 before we can begin any useful trials using our own P1 safety data. These are the facts relating to a potential treatment for Covid.
Completed Covid-19 Research Project Delivers Encouraging Results
Cambridge, UK, 1 July 2021 – Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, is pleased to announce encouraging top-line results from its UKRI grant funded Covid-19 research project.
The aim of this research project was to investigate the effects of SDC-1801, the Company’s proprietary TYK2/JAK1 inhibitor, on cytokine signalling after SARS-CoV-2 infection. It was also designed to confirm whether an over-active inflammatory response (known as a ‘cytokine storm’) via the Interferon Type 1 pathway can be blocked in this disease by SDC-1801.
The project has completed on schedule, with the final results confirming the initial encouraging results as noted in the Company’s Interim Results, published on 23 April 2021. The results of the project found that SDC-1801 reduced the levels of cytokines associated with Acute Respiratory Distress Syndrome (ARDS) in human lung cells infected with SARS-CoV-2 and demonstrated a profile that was superior to the anti-inflammatory steroid dexamethasone and similar to baricitinib, a JAK1/JAK2 inhibitor.
Subsequent completed in-vivo studies support the initial cellular results and indicate:
Strong evidence that expression of Type 1 interferons (IFNa and IFNb) is reduced by SDC-1801 treatment in a dose-responsive manner; and thatViral loads did not increase after SDC-1801 administration, a potential concern when anti-inflammatory agents are used to dampen down an over-active immune response
A secondary objective, the investigation into whether treatment with SDC-1801 in disease models could protect against bacterial pneumonia following SARS-CoV-2 infection was inconclusive, due to technical shortcomings in the disease model.
Subject to successful completion of the ongoing preclinical toxicology studies, requisite approvals and financing, the Company aims to commence Phase 1 clinical trials for SDC-1801 in early 2022. The timing and design of the clinical trials for Covid-19 applications will be determined following consultations with experts in the field.
You are welcome.
Ndr give me 5 minutes to respond.
Xviolet the only reason I’ve become downbeat as regards the potential for a Covid treatment is due to the lack of prompt action on behalf of our BOD for whatever reason they may have had and the reporting of various treatments by pharma that are currently being trialled. It may well be the case that some people may still suffer from a cytokine storm due to Covid and their underlying genetics. But if treatments are found that prevent infected people ending up in hospital then the need to be treated with 1801 will not be necessary in the case of Covid. This all of course remains to be seen either way in the course of time. Cytokine storms are caused by other viral and bacterial infections as well as Covid and this may be a use for 1801. Let us first see it get through the toxicology tests and phase 1 trials before we get too excited about what indications it may or may not treat.
ndr50
and thanks for replying. and big yes re tyk2 - although its taking me a long time to research and understand this material.
for me, investing in covid is a bit like investing in electric car batteries.
hope i'm wrong though.
ndr50
For me the potential re Covid is based on my understanding that Covid - vaccines, masks, social distancing - all that sh*t, is going to be with us, in one form or another, for the next 10-25 years.
WIP There has also been great excitement amongst LTHs concerning Covid this year. Comparisons with other Covid stocks, massive share price increases on the presumption of the start of Agile for 1801 and projected revenue for our Covid pill. It’s all been here on this bb during the last year. It’s just fortunate that the treatment for Covid is a secondary indication. As I said before the potential for this Covid opportunity may have been missed due to timing but the advent of different strains in the future may mean we still have a part to play. To suggest that new investors were just buying a Covid stock is somewhat belittling most would be looking at the potential value for Sar in the near and long term. The science for Tyk2 is compelling let’s all hope that Sar can utilise its unique IP and add value for shareholders in the future. There is an element of crystal ball comments as well as the dire dismal unsubstantiated ones designed to disrupt neither serve much purpose. Science, facts concerning the pharma sector relating to our compounds and Sar’s RNSs are the only aspects that will have a direct bearing on the value of Sareum.
Good news for Sareum - Covid has always been a side play, no matter what the one hit wonders say who are still spiked at 9.5p.
Genuine LTH’s I’d guess are more excited about autoimmune and cancer Tyk2’s, and have been for a few years. I know I am.
If I’m brutally honest, Covid a been a bit of a pain on this board as every ‘expert’ and their dog arrived having bought in after reading Covid in an RNS. Queue the stampede.
Yes we now discuss it as it’s still a huge potential, for our Tyk2. But autoimmune, cancer and the delivery method is where our money is. Long term too. I don’t mean for the next 2 years while Faucci’s GOF mess is cleaned up.
I’ve said it before, we genuinely have the potential to be a watershed in medical treatment
If you check Activ 2 - the US govt's program to fast-track Covid therapeutics - the end date for the project to evaluate some potential treatments, as far as I can tell is Dec 31st 2023. See link below. That date tells me there is no rush regarding bringing Covid therapeutics to market. (And I know that SAR is not a Covid play or at least not exclusively) But anyway, that date also suggests something rather bleak regarding Covid and the next few years. But it gives me a very clear message about the market for Covid therapeutics - it may be open for a very very long time. But hey I can just as easily be wrong. Feedback and correction welcome.
https://clinicaltrials.gov/ct2/show/NCT04518410